In last trading session, Alkermes plc (NASDAQ:ALKS) saw 1,870,280 shares changing hands with its beta currently measuring 1.48. Company’s recent per share price level of $19.27 trading at $0.2 or 1.39% at ring of the bell on the day assigns it a market valuation of $3.06 Billion. That closing price of ALKS’s stock is at a discount of -31.55% from its 52-week high price of $25.35 and is indicating a premium of 37.83% from its 52-week low price of $11.98. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.58 Million shares which gives us an average trading volume of 1.6 Million if we extend that period to 3-months.
For Alkermes plc (ALKS), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.9. Splitting up the data highlights that, out of 12 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 11 suggested the stock as a Hold whereas 1 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.01 in the current quarter.
Alkermes plc (NASDAQ:ALKS) trade information
Upright in the green today for gaining 1.39%, in the last five days ALKS remained trading in the green while hitting it’s week-highest on Thursday, Jun 25 when the stock touched $19.77- price level, adding 2.55% to its value on the day. Alkermes plc’s shares saw a change of -5.54% in year-to-date performance and have moved 8.56% in past 5-day. Alkermes plc (NASDAQ:ALKS) showed a performance of 14.29% in past 30-days. Number of shares sold short was 11.44 Million shares which calculate 7.15 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $18.82 to the stock, which implies targetted prices is already lagging behind -2.34% to its current value. Analysts have been projecting $16 as a low price target for the stock while placing it at a high target of $26. It follows that stock’s current price would jump +34.92% in reaching the projected high whereas dropping to the targeted low would mean a loss of -16.97% for stock’s current value.
Alkermes plc (ALKS) estimates and forecasts
Statistics highlight that Alkermes plc is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -9.93% of value to its shares in past 6 months, showing an annual growth rate of -107.04% while that of industry is 9.5. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -111.1% in the current quarter and calculating 75% increase in the next quarter. This year revenue growth is estimated to drop -15.9% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $231.34 Million for the same. And 9 analysts are in estimates of company making revenue of $238.52 Million in the next quarter that will end in September 01, 2020. Company posted $279.9 Million and $255.24 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -17.3% while estimating it to be -6.6% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -43.3% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -39.4% while estimates for its earnings growth in next 5 years are of 24%
Alkermes plc (NASDAQ:ALKS)’s Major holders
Insiders are in possession of 0.92% of company’s total shares while institution are holding 96.66% percent of that, with stock having share float percentage of 97.55%. Investors also watch the number of corporate investors in a company very closely, which is 317 institutions for Alkermes plc that are currently holding shares of the company. Price (T.Rowe) Associates Inc is the top institutional holder at ALKS for having 24.11 Million shares of worth $347.61 Million. And as of March 30, 2020, it was holding 15.19% of the company’s outstanding shares.
The second largest institutional holder is Wellington Management Company, LLP, which was holding about 21.93 Million shares on March 30, 2020. The number of shares represents firm’s hold over 13.82% of outstanding shares, having a total worth of $316.27 Million.
On the other hand, Vanguard Specialized-Health Care Fund and Price (T.Rowe) Mid Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of January 30, 2020, the former fund manager was holding 13352397 shares of worth $232.47 Million or 8.41% of the total outstanding shares. The later fund manager was in possession of 7.49 Million shares on March 30, 2020, making its stake of worth around $108.07 Million in the company or a holder of 4.72% of company’s stock.